A recent report demonstrated immune heterogeneityof hepatocellular carcinoma (HCC) (1). The objectiveresponse rates of sorafenib-treated global and Asian patientsby nivolumab, the monoclonal antibody to programmedcell death protein-1, were only 14% and 15%, respectively(2,3).
展开▼